Table 1.
Logistic regression predicting likelihood of nivolumab response.
| (%) | B | SE | Wald | df | P | Odds ratio | 95% CI for odds ratio | |
|---|---|---|---|---|---|---|---|---|
| Lower | Upper | |||||||
| T = 0 | ||||||||
| CD3+ | 0.205 | 0.094 | 4.790 | 1.000 | 0.029 | 1.228 | 1.022 | 1.475 |
| KIR2DL2/DL3+NKs | −0.074 | 0.037 | 3.932 | 1.000 | 0.047 | 0.929 | 0.863 | 0.999 |
| Helios+Tregs | −0.038 | 0.017 | 5.024 | 1.000 | 0.025 | 0.963 | 0.932 | 0.995 |
| Constant | −11.610 | 6.212 | 3.493 | 1.000 | 0.062 | 0.000 | ||
| T = 1 month of treatment | ||||||||
| CD3+ | 0.144 | 0.064 | 5.119 | 1.000 | 0.024 | 1.155 | 1.019 | 1.309 |
| KIR2DL2/DL3+NKs | −0.066 | 0.032 | 4.185 | 1.000 | 0.041 | 0.936 | 0.878 | 0.997 |
| ICOS+Tregs | −0.033 | 0.024 | 1.865 | 1.000 | 0.172 | 0.968 | 0.923 | 1.014 |
| Constant | −8.031 | 4.726 | 2.888 | 1.000 | 0.089 | 0.000 | ||
Multivariate logistic regression method enter; variable or predictor at basal level: % CD3+, % KIR2DL2/DL3+NKs and % Helios+Tregs; variable or predictor after 1 month of treatment: % CD3+, % KIR2DL2/DL3+NKs and % ICOS+Tregs; P value significance < 0.05; B: the estimated coefficient; SE: standard error around the co‐efficient. Wald chi-square statistics; df: degree of freedom for Wald chi-square statistics; Exp (B): exponentiation of B coefficient is an OR predicted change in odds for a unit increase in the predictor; CI: 95% confidence interval for the odds ratio with its upper and lower limits.